These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 21615854)

  • 21. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
    Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current indications for chemotherapy in prostate cancer patients.
    Calabrò F; Sternberg CN
    Eur Urol; 2007 Jan; 51(1):17-26. PubMed ID: 17007996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel?
    Oudard S; Banu E; Medioni J; Scotte F; Banu A; Levy E; Wasserman J; Kacso G; Andrieu JM
    BJU Int; 2009 Jun; 103(12):1641-6. PubMed ID: 19210673
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health-related quality of life in patients with hormone refractory prostate cancer receiving gefitinib.
    Curigliano G; Spitaleri G; De Cobelli O; Scardino E; Sbanotto A; de Braud F
    Urol Int; 2009; 82(2):196-202. PubMed ID: 19322010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer.
    Berry WR
    Urology; 2005 Jun; 65(6 Suppl):2-7. PubMed ID: 15939076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study.
    Eymard JC; Oudard S; Gravis G; Ferrero JM; Theodore C; Joly F; Priou F; Krakowski I; Zannetti A; Thill L; Beuzeboc P
    BJU Int; 2010 Oct; 106(7):974-8. PubMed ID: 20230389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impacts of leuprolide acetate on quality of life in patients with prostate cancer: a prospective multicenter study.
    You D; Jeong IG; Kim SW; Chung BH; Cho JS; Lee HM; Yun SC; Kim CS
    Scand J Urol Nephrol; 2010 Dec; 44(6):399-405. PubMed ID: 20707648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer.
    Mountzios I; Bournakis E; Efstathiou E; Varkaris A; Wen S; Chrisofos M; Deliveliotis C; Alamanis C; Anastasiou I; Constantinides C; Karadimou A; Tsiatas M; Papadimitriou C; Bamias A; Dimopoulos MA
    Urology; 2011 Mar; 77(3):682-7. PubMed ID: 21256546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.
    Berry W; Eisenberger M
    Oncologist; 2005; 10 Suppl 3():30-9. PubMed ID: 16368869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma chromogranin A: clinical implications in patients with castrate resistant prostate cancer receiving docetaxel chemotherapy.
    Sarkar D; Singh SK; Mandal AK; Agarwal MM; Mete UK; Kumar S; Mavuduru RS; Prasad R
    Cancer Biomark; 2010-2011; 8(2):81-7. PubMed ID: 21896995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer.
    Sella A; Sternberg CN; Skoneczna I; Kovel S
    BJU Int; 2008 Dec; 102(11):1607-9. PubMed ID: 18990177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quality of life in patients with skeletal metastases of prostate cancer and status prior to start of endocrine therapy: results from the Scandinavian Prostate Cancer Group Study 5.
    Jønler M; Nielsen OS; Groenvold M; Hedlund PO; Damber L; Hedelin H; Waldén M;
    Scand J Urol Nephrol; 2005; 39(1):42-8. PubMed ID: 15764270
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer.
    Ferrero JM; Chamorey E; Oudard S; Dides S; Lesbats G; Cavaglione G; Nouyrigat P; Foa C; Kaphan R
    Cancer; 2006 Aug; 107(4):738-45. PubMed ID: 16826591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial.
    Fizazi K; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houedé N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Lagrange JL; Chinet-Charrot P; Linassier C; Deplanque G; Beuzeboc P; Geneve J; Davin JL; Tournay E; Culine S
    Eur J Cancer; 2012 Jan; 48(2):209-17. PubMed ID: 22119204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy.
    Harland S; Staffurth J; Molina A; Hao Y; Gagnon DD; Sternberg CN; Cella D; Fizazi K; Logothetis CJ; Kheoh T; Haqq CM; de Bono JS; Scher HI;
    Eur J Cancer; 2013 Nov; 49(17):3648-57. PubMed ID: 23973186
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate cancer active surveillance and health-related quality of life: results of the Finnish arm of the prospective trial.
    Vasarainen H; Lokman U; Ruutu M; Taari K; Rannikko A
    BJU Int; 2012 Jun; 109(11):1614-9. PubMed ID: 22044485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quality of life and pain relief in men with metastatic castration-resistant prostate cancer on cabazitaxel: the non-interventional 'QoLiTime' study.
    Hofheinz RD; Lange C; Ecke T; Kloss S; Linsse B; Windemuth-Kieselbach C; Hammerer P; Al-Batran SE
    BJU Int; 2017 May; 119(5):731-740. PubMed ID: 27618249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paclitaxel, estramustine and carboplatin combination chemotherapy after initial docetaxel-based chemotherapy in castration-resistant prostate cancer.
    Sella A; Yarom N; Zisman A; Kovel S
    Oncology; 2009; 76(6):442-6. PubMed ID: 19420966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient-reported quality of life during radiation treatment for localized prostate cancer: results from a prospective phase II trial.
    Chen RC; Zhang Y; Chen MH; McMahon E; Loffredo M; McPherson CP; Nguyen AU; Nguyen PL; D'Amico AV
    BJU Int; 2012 Dec; 110(11):1690-5. PubMed ID: 22502770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients.
    Buonerba C; Federico P; D'Aniello C; Rescigno P; Cavaliere C; Puglia L; Ferro M; Altieri V; Perdonà S; De Placido S; Di Lorenzo G
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1455-61. PubMed ID: 21365219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.